Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumors.
|
31770456 |
2020 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
ABCB1 is one of the major drug efflux transporters that is known to cause multidrug resistance (MDR) in cancer patients receiving chemotherapy for the treatment of solid tumors and hematological malignancies.
|
30641875 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Co-expression of HIF-1α, MDR1 and LAPTM4B in peripheral blood of solid tumors.
|
30746305 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
ABCB1 have a role in the prediction of treatment response and toxicity of chemotherapy in solid tumors.
|
31571407 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cryptophycins are highly promising drug candidates, as their biological activity is not negatively affected by P-glycoprotein, a drug efflux system commonly found in multidrug-resistant cancer cell lines and solid tumors.
|
28661555 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and in particular of ABCB1 (P-glycoprotein or MDR1) is a well-known resistance mechanism for a plethora of cancer chemotherapeutics including for example taxenes, anthracyclines, Vinca alkaloids, and epipodopyllotoxins, demonstrated by a large array of published papers, both in tumor cell lines and in a variety of tumors, including various solid tumors and hematological malignancies.
|
29145976 |
2017 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Finally, we found that the ABCB1 gene was overexpressed in different generations of solid tumors.
|
23735077 |
2013 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
To date, analyses of MDR1 levels in solid tumors have examined constitutive increases in expression at relapse.
|
10589744 |
1999 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
MDR1 expression has been shown for numerous solid tumors and for virtually all hematologic malignancies.
|
9541688 |
1998 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Using Pgp and MRP as molecular markers to detect MDR tumor cells is technically demanding, and solid tumors in particular contain heterogeneous cell populations.
|
9272126 |
1997 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These cell lines represent a model of a solid tumor in which overexpression of Pgp, a combination of increased Pgp and decreased topoII alpha, and a decrease of topoII alpha are represented.
|
9393588 |
1997 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The MDR1 gene is involved in drug resistance in many hematopoietic and solid tumors.
|
8891227 |
1996 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In this article, the authors examine the literature and summarize the various techniques used to measure MDR1 gene expression, patterns of expression in adult solid tumors.
|
7642464 |
1995 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We investigated the feasibility and sensitivity of a method for probing Pgp-mediated drug transport in cells isolated from solid tumors, using xenograft models.
|
7790125 |
1995 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Preliminary studies demonstrated the presence of P-gp in tumor samples from patients with acute leukemia, multiple myeloma, lymphomas, and a variety of solid tumors.
|
8097038 |
1993 |